Phase 1 DSP-0390 With Atezolizumab for Small Cell Lung Cancer
Summary
ClinicalTrials.gov registered a Phase 1 study (NCT07545954) evaluating the safety and preliminary efficacy of EBP inhibitor DSP-0390 in combination with atezolizumab for maintenance therapy in patients with extensive-stage small cell lung cancer. The trial enrolls patients whose disease has not progressed after initial induction therapy with platinum-based chemotherapy and anti-PD-L1 immunotherapy (atezolizumab or durvalumab). The study hypothesis is that inhibition of de novo cholesterol synthesis by DSP-0390 when combined with atezolizumab will be tolerable in this patient population.
“This trial is testing the hypothesis that inhibition of de novo cholesterol synthesis by DSP-0390 when used in combination with atezolizumab in the maintenance therapy of patients with ES-SCLC will be tolerable.”
About this source
GovPing monitors ClinicalTrials.gov Studies for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 686 changes logged to date.
What changed
This Phase 1b clinical trial registration (NCT07545954) describes a single-center study evaluating DSP-0390, an EBP inhibitor targeting de novo cholesterol synthesis, in combination with atezolizumab for maintenance therapy in extensive-stage small cell lung cancer patients who have not progressed after initial platinum-based chemotherapy and anti-PD-L1 immunotherapy. The trial includes a safety lead-in component and is currently listed as Phase 1 with an April 2026 status.
For pharmaceutical manufacturers and clinical investigators, this registry entry signals ongoing research into lipid metabolism pathways as an adjunct to checkpoint inhibition in SCLC. Sponsors developing similar EBP inhibitors or studying cholesterol synthesis inhibition in oncology should monitor enrollment outcomes and safety data from this trial for potential competitive or therapeutic pathway insights.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer
Phase 1 NCT07545954 Kind: PHASE1 Apr 22, 2026
Abstract
This is a single center pilot, phase Ib study with a safety lead-in evaluating the safety and preliminary efficacy of the EBP inhibitor DSP-0390 in combination with atezolizumab in patients with extensive stage small cell lung cancer (ES-SCLC) whose disease has not progressed after initial induction therapy with platinum-based chemotherapy and anti-PD-L1 immunotherapy (atezolizumab or durvalumab per treating physician's discretion). This trial is testing the hypothesis that inhibition of de novo cholesterol synthesis by DSP-0390 when used in combination with atezolizumab in the maintenance therapy of patients with ES-SCLC will be tolerable.
Conditions: Small-cell Lung Cancer, Small Cell Lung Cancer Extensive Stage
Interventions: DSP-0390, Atezolizumab
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.